(NYSE MKT:CATX), Updated interim results with an additional ~13 weeks of follow-up since the prior update [212Pb]VMT-α-NET continues to be well-tolerated Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.1 in the first 23 patients in Cohort 2 and both patients in Cohort 1 Objective response in 39% of […]

(NYSE:HRB), KANSAS CITY, Mo., Jan. 09, 2026 (GLOBE NEWSWIRE) — H&R Block (NYSE: HRB) today announced it will include Tax Pro Review services at no additional cost in its paid DIY online tax products for new clients through February 15. This offer supports digital-first filers while leveraging the company's 70-year legacy of professional tax expertise.

(NasdaqGM:AQST), Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency's review of Anaphylm NDA application is ongoing and no final FDA decision has been made Progresses global regulatory expansion activities in Canada, Europe, and the United Kingdom for Anaphylm

IRVINE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) — iHerb Holdings, LLC, one of the world's largest online retailers specializing in health and wellness, today announced that it has completed its acquisition of Vitacost.com, Inc. (“Vitacost”) from The Kroger Co. (“Kroger”). This acquisition is expected to significantly accelerate iHerb's market presence in the U.S. and firmly

DUBAI, United Arab Emirates, Jan. 09, 2026 (GLOBE NEWSWIRE) — Presales rarely stay quiet once momentum builds. When demand keeps rising across multiple stages, later phases tend to move faster and attract more attention. That is exactly what is happening with Mutuum Finance (MUTM). Since early 2025, the project has recorded steady growth rather than

(NASDAQ:CCBG), TALLAHASSEE, Fla., Jan. 09, 2026 (GLOBE NEWSWIRE) — Capital City Bank Group, Inc. (NASDAQ: CCBG) announced today that it will release fourth quarter and year-end 2025 results on Tuesday, January 27, 2026, before the market opens. Upon release, investors may access a copy of the earnings results at the Company's Investor Relations website, investors.ccbg.com.

(NASDAQ:TLSA), BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Chief Executive Officer Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum, organized by Sachs Associates. The presentation

ADELAIDE, Australia, Jan. 09, 2026 (GLOBE NEWSWIRE) — Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, announced today that its executive team will attend Biotech Showcase 2026 in San Francisco, January 12-14, to meet with innovative biotech sponsors and highlight the company's newly launched

(NASDAQ:IMCR), Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global market penetration Enrolling three Phase 3 trials across multiple melanoma indications – TEBE-AM enrollment completion anticipated 1H 2026; topline data expected as early as 2H 2026

PRESS RELEASE Memo Therapeutics AG Publishes BKPyV Infection Disease Burden Study in the Journal of Patient-Reported Outcomes First conceptual model demonstrating the impact of BK polyomavirus on the health-related quality of life of kidney transplant recipients Study conducted in partnership with Northwestern University and presented at the World Transplant Congress in August 2025 Schlieren /